UPDATE 1-NewLink's pancreatic cancer therapy fails late-stage study

May 9 (Reuters) - NewLink Genetics Corp said on
Monday its experimental pancreatic cancer immunotherapy did not
meet the main goal in a late-stage study, sending its shares
tumbling 36 percent in...